Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

Phosphodiesterases (PDEs), enzymes that degrade 3′, 5′-cyclic nucleotides, are being
pursued as therapeutic targets for several diseases, including those affecting the nervous …

Nitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical
functions in the body. There are markedly conflicting findings in the literature regarding the …

The phosphodiesterase 4 (PDE4) enzyme family plays a pivotal role in regulating levels of
the second messenger cAMP. Consequently, PDE4 inhibitors have been investigated as a …

Monoclonal antibodies have evolved from research tools to powerful therapeutics in the past
30 years. Clinical success rates of antibodies have exceeded expectations, resulting in …

Phosphodiesterases (PDE) are a diverse family of enzymes (11 isoforms so far identified)
responsible for the degradation of cyclic adenosine monophosphate (cAMP) and cyclic …

According to the World Health Organization (WHO), 422 million people are suffering from
diabetes worldwide. Current diabetes therapies are focused on optimizing blood glucose …

As antibody–drug conjugates have become a very important modality for cancer therapy,
many site-specific conjugation approaches have been developed for generating …

Unnatural amino acids have gained significant attention in protein engineering and drug
discovery as they allow the evolution of proteins with enhanced stability and activity. The …